FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

被引：0
作者：
Iravani, Amir
Wallace, Roslyn
Lo, Serigne
Galligan, Anna
Weppler, Alison
Au-Yeung, George
Kee, Damien
Lau, Peter Kar Han
Brady, Benjamin M.
Lee, Belinda
McArthur, Grant A.
Sandhu, Shahneen Kaur
Hicks, Rodney J.
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10041
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma
    De Barros E Silva, Milton Jose
    Tavares, Monique Celeste
    Lima, Joao Paulo S. N.
    Buzaid, Antonio C.
    Garcia, Daniel
    De Camargo, Veridiana Pires
    Molina, Andre
    Bertolli, Eduardo
    Lobo, Matheus
    Jonathan Van Akkooi, Alexander Christopher
    Pinto, Clovis
    De Paula, Rafaela Brito
    Lima, Eduardo
    Rinck, Jose Augusto
    Duprat, Joao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)
    Hodi, F. S.
    Gibney, G.
    Sullivan, R.
    Sosman, J. A.
    Slingluff, C. L., Jr.
    Lawrence, D. P.
    Logan, T. F.
    Schuchter, L. M.
    Nair, S.
    Fecher, L.
    Buchbinder, E.
    Ruisi, M.
    Kong, G.
    Horak, C.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S721 - S721
  • [33] Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO plus RELA plus IPI) in advanced melanoma: Results from RELATIVITY-048.
    Ascierto, Paolo Antonio
    Dummer, Reinhard
    Gaudy-Marqueste, Caroline
    Bowyer, Samantha
    Lipson, Evan J.
    Ghisoni, Eleonora
    Middleton, Mark R.
    Ratto, Barbara
    Jackson, William Joseph
    Cheong, Alicia
    Mukherjee, Sourav
    Wu, Jenny
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
    Lebbe, Celeste
    Meyer, Nicolas
    Mortier, Laurent
    Marquez-Rodas, Ivan
    Robert, Caroline
    Rutkowski, Piotr
    Butler, Marcus O.
    Eigentler, Thomas
    Menzies, Alexander M.
    Smylie, Michael
    Arance, Ana Maria
    Ascierto, Paolo Antonio
    Svane, Inge Marie
    Ajaz, Mazhar
    Khushalani, Nikhil I.
    Lobo, Maurice
    Zoco, Jesus
    Pigozzo, Jacopo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 68 - 68
  • [36] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Hogg, David
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Smylie, Michael
    Kudchadkar, Ragini Reiney
    Thompson, John A.
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Role of Metabolic Tumor Volume and Total Lesion Glycolysis on FDG-PET/CT in NSCLC treated with SBRT
    Cabrera, J.
    Infante, J.
    Cruz, C.
    Moreno, M.
    Gonzalez, M.
    Rayo, J.
    Simon, P.
    Ortiz, B.
    Munoz, J.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S754 - S755
  • [38] Real World Data on the Use of Nivolumab (Nivo) as Monotherapy or in Combination with Ipilimumab (Nivo plus Ipi) in the Treatment of advanced Melanoma: Interim Results of the non-interventional Study NICO
    Ugurel, S.
    Satzger, I.
    Eigentler, T.
    Mohr, P.
    Goeppner, D.
    Herber, M.
    Herbst, R.
    Kaehler, K. C.
    Meier, F.
    Meiss, F.
    Pfoehler, C.
    Sachse, M. M.
    Schneider, S. W.
    Terheyden, P.
    Ulrich, J.
    Utikal, J. S.
    Welzel, J.
    Schadendorf, D.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 69 - 70
  • [39] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 28 - 28
  • [40] Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.
    Larkin, James
    Gogas, Helen
    Del Vecchio, Michele
    Maio, Michele
    Arenberger, Petr
    Arance, Ana Maria
    Grob, Jean-Jacques
    Chiarion-Sileni, Vanna
    Lewis, Karl D.
    Mortier, Laurent
    Ott, Patrick Alexander
    Long, Georgina V.
    Van Den Eertwegh, Alfonsus
    Cowey, C. Lance
    Schenker, Michael
    Butler, Marcus O.
    Lobo, Maurice
    Askelson, Margarita
    Ascierto, Paolo Antonio
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345